Mark Sabag is VP at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). They have made 9 open-market trades across 1 company since 2018, most recently 2026-05-01.
CIK 0001721442
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TEVA | 80,760 | $3.3M |
Shares reported on the most recent Form 4, priced at the 2026-05-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TEVA | SELL | 2026-05-01 | 2026-05-04 | $34.99 | $5.0M | -0.4% | -7.4% | -2.9% |
| TEVA | SELL | 2026-03-17 | 2026-03-19 | $30.14 | $3.7M | +1.6% | +8.0% | +9.8% |
| TEVA | SELL | 2025-12-09 | 2025-12-11 | $28.72 | $9.0M | +5.1% | +9.3% | +1.6% |
| TEVA | SELL | 2025-05-08 | 2025-05-12 | $18.04 | $12.2M | -4.7% | -2.5% | -7.6% |
| TEVA | SELL | 2025-02-12 | 2025-02-14 | $16.25 | $5.8M | -4.8% | -2.6% | -1.6% |
| TEVA | SELL | 2024-03-05 | 2024-03-07 | $13.52 | $1.4M | -2.5% | +3.7% | +23.3% |
| TEVA | SELL | 2021-03-16 | 2021-03-17 | $11.22 | $2.9M | -1.6% | -6.7% | -5.8% |
| TEVA | SELL | 2020-02-13 | 2020-02-18 | $13.03 | $1.9M | -7.9% | -42.7% | -6.0% |
| TEVA | SELL | 2018-02-14 | 2018-02-20 | $19.68 | $99K | -4.1% | -13.4% | +5.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.